For sales

📢Highlights from the Week of 15th–22nd September 2025  in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of 15th–22nd September Incyte ( FDA, Approval ) Incyte’s OPZELURA is now the first topical JAK inhibitor approved by the FDA to treat atopic dermatitis in children ages 2 to 11 Johnson and Johnson ( FDA, Approval ) FDA approves SC induction of TREMFYA, the first IL-23 inhibitor with both SC and IV options for UC and CD Merck ( FDA, Approval ) FDA approves KEYTRUDA QLEX, an SC formulation of pembrolizumab with hyaluronidase, for adults across most solid tumor indications KalVista Pharmaceuticals ( EMA, Approval ) KalVista Pharmaceuticals’ EKTERLY has been approved in the EU & Switzerland for acute hereditary angioedema attacks; first oral on-demand HAE therapy All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.